政府降价将继续 在旧体制下听惯政府号子的医药企业谁的账都可以不买,政府的声音却无论如何也不能不听,在“医改”的关键时刻同样如此。回顾从2000年年底到今年3月的有关政策动向和风声,药品降价的前景可见端倪。 2000年12月21日,国家计委有关负责人就药品医疗服务价格改革答记者问时强调:近年来,药品价格“虚高”、高折扣、大回扣推销药品等问题没有根本解决,医疗服务价格体系还没有完全理顺,乱收费问题仍很突出,社会反映强烈。该负责人同时指出,当前我国药品生产总体上是供过于求的,放开后,在正常情况下价格不会上涨。 The Government will continue to cut prices in the old system, the government’s son who can not get the accounts of the government, but the government’s voice can not but listen in any case, the same is true at the crucial moment of “medical reform.” Looking back at the relevant policy trends and winds from the end of 2000 to March of this year, the prospect of drug price cuts can be seen. On December 21, 2000, the relevant person in charge of the State Development Planning Commission, in answering a question on the price reform of pharmaceuticals and medical services, stressed: In recent years, there has been no fundamental solution to the problems of “artificially high drug prices, high discounts and big rebates to promote drugs” The price system has not been fully straightened out, the issue of indiscriminate charges is still outstanding, and the society has responded strongly. The official also pointed out that the overall current drug production in our country is oversupplied, after the release, under normal circumstances the price will not rise.